查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2028271

流感疫苗市場規模、佔有率、成長及全球產業分析：按類型、應用和地區分類的洞察，2026-2034 年預測

Influenza Vaccine Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 177 Pages | 商品交期: 2-3個工作天內

價格

流感疫苗市場成長要素

受季節性流感疫情加劇、政府免疫計畫擴大以及疫苗技術不斷進步的推動，全球流感疫苗市場正經歷強勁且持續的成長。產業預測，市場規模將在2025年達到92億美元，2026年達到99.6億美元，最終在2034年達到224.9億美元，2026年至2034年的複合年成長率（CAGR）為10.72%。

市場規模與價值概覽

市場規模的穩定成長反映了全球對預防性醫療保健和疫苗接種率日益成長的重視。流感仍對全球健康構成重大威脅，世界衛生組織（世衛組織）報告稱，每年全球約有300萬至500萬例重症流感病例，並導致29萬至65萬人死亡。這種日益嚴重的疾病負擔正直接影響已開發國家和開發中國家的疫苗需求。

到2025年，北美將以49.5億美元的市場規模引領全球市場，佔全球整體佔有率的53.79%。該地區預計將保持強勁成長，這得益於其先進的醫療基礎設施、創新疫苗的早期部署以及由美國疾病控制與預防中心（CDC）和世界衛生組織全球流感監測和應對系統（GISRS）等機構主導的強力的宣傳宣傳活動。

區域趨勢

北美地區持續保持著流感高發生區的地位，這主要得益於該地區流感發​​病率高和疫苗接種率高。光是在美國，2021年就記錄了約3720萬例流感病例，凸顯了年度疫苗接種計畫的必要性。

歐洲是第二大市場，這得益於政府的採購舉措和大規模疫苗接種計畫。預計該地區2025年市場規模將達24.5億美元，2026年將達26.3億美元。同時，亞太地區正崛起為成長最快的地區，這主要得益於醫療保健覆蓋範圍的擴大、龐大的人口基數以及政府主導的疫苗宣傳活動運動的增加，尤其是在中國和印度。

市場促進因素

推動疫苗成長要素之一是政府對免疫接種計畫的支持增加。美國疾病管制與預防中心（CDC）、世界衛生組織（WHO）以及各國衛生署等機構正積極進行宣傳宣傳活動和免費免疫接種項目，以促進疫苗接種。例如，「幫助他們對抗流感」等措施已顯著提高了兒童和高風險族群的疫苗接種率。

另一個主要驅動力是研發投入的增加。製藥公司正致力於研發下一代疫苗，例如mRNA疫苗和同時針對流感和新冠病毒的聯合疫苗。 2021年，杜克大學的研究人員開發了一種基於mRNA的實驗性聯合疫苗，可同時針對這兩種病毒，凸顯了未來創新的潛力。

行業趨勢和主要公司

流感疫苗市場競爭非常激烈，各大製藥公司都在擴大生產能力，並投資先進的疫苗平台。

主要行業參與者包括：

  • 全球流感疫苗領導者賽諾菲憑藉其「Fluzone 高劑量四價流感疫苗」和「Flublok 四價流感疫苗」獲得 2022-2023 流感季的核准，進一步鞏固了其市場地位。
  • GlaxoSmithKline Plc在歐洲的疫苗供應合約和大規模生產舉措中發揮關鍵作用。
  • Astra Zeneca持續透過流感疫苗的創新做出貢獻，包括鼻噴霧疫苗技術。
  • CSL有限公司正在對研發設施和下一代基於mRNA的流感疫苗進行大量投資。
  • 科興生物透過國際投資擴大了全球疫苗生產能力。
  • Abbott 和 Viatlis 持續支援全球分銷網路。
  • Biken株式會社為日本流感疫苗的研發做出了重大貢獻。

市場區隔趨勢

四價疫苗因其對多種流感病毒株的廣泛保護作用而佔市場主導地位，預計到 2025 年將佔最大佔有率。去活化疫苗也預計在 2026 年引領該領域，市佔率超過 92%，這得益於其良好的安全性和廣泛的監管核准。

按年齡層別分類，成人疫苗佔很大比例，因為老年人群風險較高；而隨著開發中國家疫苗接種率的提高，預計兒童疫苗將迅速成長。

目錄

第1章：引言

第2章摘要整理

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第4章：主要考慮因素

  • 主要國家流感疫苗接種率概況 - 2025 年
  • 2025/2025 年主要國家和地區流感年度疾病負擔
  • 新產品發布：按主要公司分類
  • 政府實施的流感疫苗接種宣傳活動/計劃
  • 產業重大發展動態－併購與合作
  • 價格分析 - 按主要品牌/公司、主要國家/地區分類，2025/2025 年
  • 流感疫苗開發平臺分析概述
  • 新冠疫情對市場的影響

第5章：2021-2034年全球流感疫苗市場分析、洞察與預測

  • 市場分析、洞察與預測：按類型
    • 失活
    • 活病毒疫苗
  • 市場分析、洞察與預測：按價格範圍分類
    • 四價
    • 三價
  • 市場分析、洞察與預測：按年齡層別分類
    • 兒童
    • 成人
  • 市場分析、洞察與預測：按分銷管道分類
    • 醫院和零售藥局
    • 政府關聯供應商
    • 其他
  • 市場分析、洞察與預測：按地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章：北美流感疫苗市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章：歐洲流感疫苗市場分析、洞察與預測（2021-2034年）

  • 國家
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪地那維亞
    • 其他歐洲國家

第8章：亞太地區流感疫苗市場分析、洞察與預測（2021-2034年）

  • 國家
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 其他亞太國家

第9章：拉丁美洲流感疫苗市場分析、洞察與預測（2021-2034年）

  • 國家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第10章：中東和非洲流感疫苗市場分析、洞察與預測（2021-2034年）

  • 國家
    • 海灣合作理事會國家
    • 南非
    • 其他中東和非洲國家

第11章 競爭分析

  • 全球市佔率分析（2025 年）
  • 公司簡介
    • AstraZeneca
    • CSL Limited（Seqirus）
    • GlaxoSmithKline plc
    • Sanofi
    • SINOVAC
    • BIKEN Co., Ltd.
    • Abbott
    • Viatris Inc.
Product Code: FBI101896

Growth Factors of influenza vaccine Market

The global influenza vaccine market is witnessing strong and sustained growth, driven by increasing seasonal outbreaks, rising government immunization programs, and continuous advancements in vaccine technologies. According to industry estimates, the market was valued at USD 9.2 billion in 2025 and is projected to reach USD 9.96 billion in 2026, ultimately expanding to USD 22.49 billion by 2034, registering a CAGR of 10.72% during 2026-2034.

Market Size and Value Overview

The steady rise in market value reflects the growing global emphasis on preventive healthcare and vaccination coverage. Influenza continues to cause significant global health burdens, with the World Health Organization (WHO) reporting approximately 3 to 5 million severe influenza cases annually, leading to 290,000 to 650,000 deaths worldwide. This increasing disease burden has directly influenced vaccine demand across both developed and developing economies.

In 2025, North America dominated the global market with a value of USD 4.95 billion, accounting for 53.79% of the total global share. The region is expected to maintain strong growth due to advanced healthcare infrastructure, early adoption of innovative vaccines, and strong public awareness campaigns led by agencies such as the Centers for Disease Control and Prevention (CDC) and the WHO Global Influenza Surveillance and Response System (GISRS).

Regional Insights

North America remains the leading region, supported by high influenza incidence and strong vaccine adoption rates. The U.S. alone recorded approximately 37.2 million influenza cases in 2021, reinforcing the need for annual immunization programs.

Europe follows as the second-largest market, supported by government procurement initiatives and large-scale vaccination programs. The region accounted for USD 2.45 billion in 2025 and is expected to reach USD 2.63 billion in 2026. Asia Pacific, on the other hand, is emerging as the fastest-growing region due to expanding healthcare access, large population base, and increasing government vaccination campaigns, particularly in China and India.

Market Drivers

A key growth driver is increasing government support for immunization programs. Organizations such as the CDC, WHO, and national health ministries are actively promoting vaccination through public awareness campaigns and free immunization drives. For example, initiatives like "Help Them Fight Flu" have significantly improved vaccination coverage among children and high-risk populations.

Another major driver is rising research and development investment. Pharmaceutical companies are focusing on next-generation vaccines, including mRNA-based and combination vaccines that target both influenza and COVID-19. In 2021, researchers at Duke University developed an experimental mRNA-based combination vaccine targeting both viruses, highlighting future innovation potential.

Industry Developments and Key Companies

The influenza vaccine market is highly competitive, with major pharmaceutical players investing in manufacturing expansion and advanced vaccine platforms.

Key industry participants include:

  • Sanofi, a global leader in influenza vaccines, strengthened its position through approvals of Fluzone High-Dose Quadrivalent and Flublok Quadrivalent for the 2022-2023 flu season.
  • GlaxoSmithKline plc plays a significant role in European vaccine supply agreements and large-scale production initiatives.
  • AstraZeneca continues to contribute through its flu vaccine innovations, including nasal spray vaccine technologies.
  • CSL Limited is investing heavily in R&D facilities and next-generation mRNA-based influenza vaccines.
  • SINOVAC expanded global vaccine production capabilities through international investments.
  • Abbott and Viatris Inc. continue to support global distribution networks.
  • BIKEN Co., Ltd. contributes significantly to influenza vaccine development in Japan.

Market Segmentation Trends

Quadrivalent vaccines dominate the market due to broader protection against multiple influenza strains, accounting for the largest share in 2025. Inactivated vaccines also lead the segment with over 92% share in 2026 due to their safety profile and wide regulatory acceptance.

By age group, adult vaccination holds a significant share due to high-risk elderly populations, while pediatric vaccination is expected to grow rapidly due to increasing immunization coverage in developing countries.

Conclusion

Between 2025 and 2034, the influenza vaccine market is expected to experience strong expansion driven by rising disease prevalence, technological advancements in vaccine development, and increasing global immunization efforts. With the market projected to grow from USD 9.2 billion in 2025 to USD 22.49 billion in 2034, the industry presents significant opportunities for pharmaceutical companies and public health organizations worldwide.

Segmentation By Type

  • Inactivated
  • Live Attenuated

By Valency

  • Quadrivalent
  • Trivalent

By Age Group

  • Pediatric
  • Adults

By Distribution Channel

  • Hospital & Retail Pharmacies
  • Government Suppliers
  • Others

By Region

  • North America (By Type, By Valency, By Age Group, By Distribution Channel, and By Country)
    • U.S. (By Valency)
    • Canada (By Valency)
  • Europe (By Type, By Valency, By Age Group, By Distribution Channel, and By Country/Sub-region)
    • U.K. (By Valency)
    • Germany (By Valency)
    • France (By Valency)
    • Italy (By Valency)
    • Spain (By Valency)
    • Scandinavia (By Valency)
    • Rest of Europe (By Valency)
  • Asia Pacific (By Type, By Valency, By Age Group, By Distribution Channel, and By Country/Sub-region)
    • Japan (By Valency)
    • Korea (By Valency)
    • China (By Valency)
    • India (By Valency)
    • Australia (By Valency)
    • Rest of Asia Pacific (By Valency)
  • Latin America (By Type, By Valency, By Age Group, By Distribution Channel, and By Country/Sub-region)
    • Brazil (By Valency)
    • Mexico (By Valency)
    • Rest of Latin America (By Valency)
  • Middle East & Africa (By Type, By Valency, By Age Group, By Distribution Channel, and By Country/Sub-region)
    • GCC (By Valency)
    • South Africa (By Valency)
    • Rest of Middle East & Africa (By Valency)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Snapshot of Influenza Vaccine Rate - For Key Countries, 2025
  • 4.2. Annual Disease Burden of Influenza - For Key Countries/ Regions, 2025/2025
  • 4.3. New Product Launches, By Key Players
  • 4.4. Influenza Vaccination Campaigns/Programs Undertaken by Government
  • 4.5. Key Industry Developments - Mergers, Acquisitions, and Partnerships
  • 4.6. Pricing Analysis - By Key Brand/Key Players, By Key Countries, 2025/2025
  • 4.7. Snapshot of Pipeline Analysis of Influenza Vaccines
  • 4.8. Impact of COVID-19 on the Market

5. Global Influenza Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Type
    • 5.1.1. Inactivated
    • 5.1.2. Live Attenuated
  • 5.2. Market Analysis, Insights and Forecast - By Valency
    • 5.2.1. Quadrivalent
    • 5.2.2. Trivalent
  • 5.3. Market Analysis, Insights and Forecast - By Age Group
    • 5.3.1. Pediatric
    • 5.3.2. Adults
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospital & Retail Pharmacies
    • 5.4.2. Government Suppliers
    • 5.4.3. Others
  • 5.5. Market Analysis, Insights and Forecast - By Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Influenza Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Type
    • 6.1.1. Inactivated
    • 6.1.2. Live Attenuated
  • 6.2. Market Analysis, Insights and Forecast - By Valency
    • 6.2.1. Quadrivalent
    • 6.2.2. Trivalent
  • 6.3. Market Analysis, Insights and Forecast - By Age Group
    • 6.3.1. Pediatric
    • 6.3.2. Adults
  • 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.4.1. Hospital & Retail Pharmacies
    • 6.4.2. Government Suppliers
    • 6.4.3. Others
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
      • 6.5.1.1. By Valency
    • 6.5.2. Canada
      • 6.5.2.1. By Valency

7. Europe Influenza Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Type
    • 7.1.1. Inactivated
    • 7.1.2. Live Attenuated
  • 7.2. Market Analysis, Insights and Forecast - By Valency
    • 7.2.1. Quadrivalent
    • 7.2.2. Trivalent
  • 7.3. Market Analysis, Insights and Forecast - By Age Group
    • 7.3.1. Pediatric
    • 7.3.2. Adults
  • 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.4.1. Hospital & Retail Pharmacies
    • 7.4.2. Government Suppliers
    • 7.4.3. Others
  • 7.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.5.1. U.K.
      • 7.5.1.1. By Valency
    • 7.5.2. Germany
      • 7.5.2.1. By Valency
    • 7.5.3. France
      • 7.5.3.1. By Valency
    • 7.5.4. Italy
      • 7.5.4.1. By Valency
    • 7.5.5. Spain
      • 7.5.5.1. By Valency
    • 7.5.6. Scandinavia
      • 7.5.6.1. By Valency
    • 7.5.7. Rest of Europe
      • 7.5.7.1. By Valency

8. Asia Pacific Influenza Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Type
    • 8.1.1. Inactivated
    • 8.1.2. Live Attenuated
  • 8.2. Market Analysis, Insights and Forecast - By Valency
    • 8.2.1. Quadrivalent
    • 8.2.2. Trivalent
  • 8.3. Market Analysis, Insights and Forecast - By Age Group
    • 8.3.1. Pediatric
    • 8.3.2. Adults
  • 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.4.1. Hospital & Retail Pharmacies
    • 8.4.2. Government Suppliers
    • 8.4.3. Others
  • 8.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.5.1. Japan
      • 8.5.1.1. By Valency
    • 8.5.2. China
      • 8.5.2.1. By Valency
    • 8.5.3. India
      • 8.5.3.1. By Valency
    • 8.5.4. Australia
      • 8.5.4.1. By Valency
    • 8.5.5. Korea
      • 8.5.5.1. By Valency
    • 8.5.6. Rest of Asia Pacific
      • 8.5.6.1. By Valency

9. Latin America Influenza Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Type
    • 9.1.1. Inactivated
    • 9.1.2. Live Attenuated
  • 9.2. Market Analysis, Insights and Forecast - By Valency
    • 9.2.1. Quadrivalent
    • 9.2.2. Trivalent
  • 9.3. Market Analysis, Insights and Forecast - By Age Group
    • 9.3.1. Pediatric
    • 9.3.2. Adults
  • 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.4.1. Hospital & Retail Pharmacies
    • 9.4.2. Government Suppliers
    • 9.4.3. Others
  • 9.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 9.5.1. Brazil
      • 9.5.1.1. By Valency
    • 9.5.2. Mexico
      • 9.5.2.1. By Valency
    • 9.5.3. Rest of Latin America
      • 9.5.3.1. By Valency

10. Middle East & Africa Influenza Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Type
    • 10.1.1. Inactivated
    • 10.1.2. Live Attenuated
  • 10.2. Market Analysis, Insights and Forecast - By Valency
    • 10.2.1. Quadrivalent
    • 10.2.2. Trivalent
  • 10.3. Market Analysis, Insights and Forecast - By Age Group
    • 10.3.1. Pediatric
    • 10.3.2. Adults
  • 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.4.1. Hospital & Retail Pharmacies
    • 10.4.2. Government Suppliers
    • 10.4.3. Others
  • 10.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 10.5.1. GCC Countries
      • 10.5.1.1. By Valency
    • 10.5.2. South Africa
      • 10.5.2.1. By Valency
    • 10.5.3. Rest of Middle East & Africa
      • 10.5.3.1. By Valency

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. AstraZeneca
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. SWOT analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. CSL Limited (Seqirus)
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. SWOT analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. GlaxoSmithKline plc
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. SWOT analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Sanofi
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. SWOT analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. SINOVAC
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. SWOT analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. BIKEN Co., Ltd.
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. SWOT analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Abbott
      • 11.2.7.1. Overview
      • 11.2.7.2. Products
      • 11.2.7.3. SWOT analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Viatris Inc.
      • 11.2.8.1. Overview
      • 11.2.8.2. Products
      • 11.2.8.3. SWOT analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)

List of Tables

  • Table 01: Global Influenza Vaccine Market Revenue (USD billion) Forecast, By Type, 2021-2034
  • Table 02: Global Influenza Vaccine Market Revenue (USD billion) Forecast, By Valency, 2021-2034
  • Table 03: Global Influenza Vaccine Market Revenue (USD billion) Forecast, By Age Group, 2021-2034
  • Table 04: Global Influenza Vaccine Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 05: Global Influenza Vaccine Market Revenue (USD billion) Forecast, By Region, 2021-2034
  • Table 06: North America Influenza Vaccine Market Revenue (USD billion) Forecast, By Type, 2021-2034
  • Table 07: North America Influenza Vaccine Market Revenue (USD billion) Forecast, By Valency, 2021-2034
  • Table 08: North America Influenza Vaccine Market Revenue (USD billion) Forecast, By Age Group, 2021-2034
  • Table 09: North America Influenza Vaccine Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 10: North America Influenza Vaccine Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 11: U.S. Influenza Vaccine Market Revenue (USD billion) Forecast, By Valency, 2021-2034
  • Table 12: Canada Influenza Vaccine Market Revenue (USD billion) Forecast, By Valency, 2021-2034
  • Table 13: Europe Influenza Vaccine Market Revenue (USD billion) Forecast, By Type, 2021-2034
  • Table 14: Europe Influenza Vaccine Market Revenue (USD billion) Forecast, By Valency, 2021-2034
  • Table 15: Europe Influenza Vaccine Market Revenue (USD billion) Forecast, By Age Group, 2021-2034
  • Table 16: Europe Influenza Vaccine Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 17: Europe Influenza Vaccine Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 18: Germany Influenza Vaccine Market Revenue (USD billion) Forecast, By Valency, 2021-2034
  • Table 19: U.K. Influenza Vaccine Market Revenue (USD billion) Forecast, By Valency, 2021-2034
  • Table 20: France Influenza Vaccine Market Revenue (USD billion) Forecast, By Valency, 2021-2034
  • Table 21: Italy Influenza Vaccine Market Revenue (USD billion) Forecast, By Valency, 2021-2034
  • Table 22: Spain Influenza Vaccine Market Revenue (USD billion) Forecast, By Valency, 2021-2034
  • Table 23: Scandinavia Influenza Vaccine Market Revenue (USD billion) Forecast, By Valency, 2021-2034
  • Table 24: Rest of Europe Influenza Vaccine Market Revenue (USD billion) Forecast, By Valency, 2021-2034
  • Table 25: Asia Pacific Influenza Vaccine Market Revenue (USD billion) Forecast, By Type, 2021-2034
  • Table 26: Asia Pacific Influenza Vaccine Market Revenue (USD billion) Forecast, By Valency, 2021-2034
  • Table 27: Asia Pacific Influenza Vaccine Market Revenue (USD billion) Forecast, By Age Group, 2021-2034
  • Table 28: Asia Pacific Influenza Vaccine Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 29: Asia Pacific Influenza Vaccine Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 30: Japan Influenza Vaccine Market Revenue (USD billion) Forecast, By Valency, 2021-2034
  • Table 31: Korea Influenza Vaccine Market Revenue (USD billion) Forecast, By Valency, 2021-2034
  • Table 32: China Influenza Vaccine Market Revenue (USD billion) Forecast, By Valency, 2021-2034
  • Table 33: India Influenza Vaccine Market Revenue (USD billion) Forecast, By Valency, 2021-2034
  • Table 34: Australia Influenza Vaccine Market Revenue (USD billion) Forecast, By Valency, 2021-2034
  • Table 35: Rest of Asia Pacific Influenza Vaccine Market Revenue (USD billion) Forecast, By Valency, 2021-2034
  • Table 36: Latin America Influenza Vaccine Market Revenue (USD billion) Forecast, By Type, 2021-2034
  • Table 37: Latin America Influenza Vaccine Market Revenue (USD billion) Forecast, By Valency, 2021-2034
  • Table 38: Latin America Influenza Vaccine Market Revenue (USD billion) Forecast, By Age Group, 2021-2034
  • Table 39: Latin America Influenza Vaccine Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 40: Latin America Influenza Vaccine Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 41: Brazil Influenza Vaccine Market Revenue (USD billion) Forecast, By Valency, 2021-2034
  • Table 42: Mexico Influenza Vaccine Market Revenue (USD billion) Forecast, By Valency, 2021-2034
  • Table 43: Rest of Latin America Influenza Vaccine Market Revenue (USD billion) Forecast, By Valency, 2021-2034
  • Table 44: Middle East & Africa Influenza Vaccine Market Revenue (USD billion) Forecast, By Type, 2021-2034
  • Table 45: Middle East & Africa Influenza Vaccine Market Revenue (USD billion) Forecast, By Valency, 2021-2034
  • Table 46: Middle East & Africa Influenza Vaccine Market Revenue (USD billion) Forecast, By Age Group, 2021-2034
  • Table 47: Middle East & Africa Influenza Vaccine Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 48: Middle East & Africa Influenza Vaccine Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 49: GCC Influenza Vaccine Market Revenue (USD billion) Forecast, By Valency, 2021-2034
  • Table 50: South Africa Influenza Vaccine Market Revenue (USD billion) Forecast, By Valency, 2021-2034
  • Table 51: Rest of Middle East & Africa Influenza Vaccine Market Revenue (USD billion) Forecast, By Valency, 2021-2034

List of Figures

  • Figure 01: Global Influenza Vaccine Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 02: Global Influenza Vaccine Market Value Share (%), By Type, 2025 & 2034
  • Figure 03: Global Influenza Vaccine Market Value Share (%), By Valency, 2025 & 2034
  • Figure 04: Global Influenza Vaccine Market Value Share (%), By Age Group, 2025 & 2034
  • Figure 05: Global Influenza Vaccine Market Value Share (%), By Distribution Channel, 2025 & 2034
  • Figure 06: Global Influenza Vaccine Market Value Share (%), By Region, 2025 & 2034
  • Figure 07: North America Influenza Vaccine Market Value (USD billion), by Type, 2025 & 2034
  • Figure 08: North America Influenza Vaccine Market Value Share (%), by Type, 2025
  • Figure 09: North America Influenza Vaccine Market Value (USD billion), by Valency, 2025 & 2034
  • Figure 10: North America Influenza Vaccine Market Value Share (%), by Valency, 2025
  • Figure 11: North America Influenza Vaccine Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 12: North America Influenza Vaccine Market Value Share (%), by Age Group, 2025
  • Figure 13: North America Influenza Vaccine Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 14: North America Influenza Vaccine Market Value Share (%), by Distribution Channel, 2025
  • Figure 15: North America Influenza Vaccine Market Value (USD billion), by Country, 2025 & 2034
  • Figure 16: North America Influenza Vaccine Market Value Share (%), by Country, 2025
  • Figure 17: Europe Influenza Vaccine Market Value (USD billion), by Type, 2025 & 2034
  • Figure 18: Europe Influenza Vaccine Market Value Share (%), by Type, 2025
  • Figure 19: Europe Influenza Vaccine Market Value (USD billion), by Valency, 2025 & 2034
  • Figure 20: Europe Influenza Vaccine Market Value Share (%), by Valency, 2025
  • Figure 21: Europe Influenza Vaccine Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 22: Europe Influenza Vaccine Market Value Share (%), by Age Group, 2025
  • Figure 23: Europe Influenza Vaccine Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 24: Europe Influenza Vaccine Market Value Share (%), by Distribution Channel, 2025
  • Figure 25: Europe Influenza Vaccine Market Value (USD billion), by Country, 2025 & 2034
  • Figure 26: Europe Influenza Vaccine Market Value Share (%), by Country, 2025
  • Figure 27: Asia Pacific Influenza Vaccine Market Value (USD billion), by Type, 2025 & 2034
  • Figure 28: Asia Pacific Influenza Vaccine Market Value Share (%), by Type, 2025
  • Figure 29: Asia Pacific Influenza Vaccine Market Value (USD billion), by Valency, 2025 & 2034
  • Figure 30: Asia Pacific Influenza Vaccine Market Value Share (%), by Valency, 2025
  • Figure 31: Asia Pacific Influenza Vaccine Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 32: Asia Pacific Influenza Vaccine Market Value Share (%), by Age Group, 2025
  • Figure 33: Asia Pacific Influenza Vaccine Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 34: Asia Pacific Influenza Vaccine Market Value Share (%), by Distribution Channel, 2025
  • Figure 35: Asia Pacific Influenza Vaccine Market Value (USD billion), by Country, 2025 & 2034
  • Figure 36: Asia Pacific Influenza Vaccine Market Value Share (%), by Country, 2025
  • Figure 37: Latin America Influenza Vaccine Market Value (USD billion), by Type, 2025 & 2034
  • Figure 38: Latin America Influenza Vaccine Market Value Share (%), by Type, 2025
  • Figure 39: Latin America Influenza Vaccine Market Value (USD billion), by Valency, 2025 & 2034
  • Figure 40: Latin America Influenza Vaccine Market Value Share (%), by Valency, 2025
  • Figure 41: Latin America Influenza Vaccine Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 42: Latin America Influenza Vaccine Market Value Share (%), by Age Group, 2025
  • Figure 43: Latin America Influenza Vaccine Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 44: Latin America Influenza Vaccine Market Value Share (%), by Distribution Channel, 2025
  • Figure 45: Latin America Influenza Vaccine Market Value (USD billion), by Country, 2025 & 2034
  • Figure 46: Latin America Influenza Vaccine Market Value Share (%), by Country, 2025
  • Figure 47: Middle East & Africa Influenza Vaccine Market Value (USD billion), by Type, 2025 & 2034
  • Figure 48: Middle East & Africa Influenza Vaccine Market Value Share (%), by Type, 2025
  • Figure 49: Middle East & Africa Influenza Vaccine Market Value (USD billion), by Valency, 2025 & 2034
  • Figure 50: Middle East & Africa Influenza Vaccine Market Value Share (%), by Valency, 2025
  • Figure 51: Middle East & Africa Influenza Vaccine Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 52: Middle East & Africa Influenza Vaccine Market Value Share (%), by Age Group, 2025
  • Figure 53: Middle East & Africa Influenza Vaccine Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 54: Middle East & Africa Influenza Vaccine Market Value Share (%), by Distribution Channel, 2025
  • Figure 55: Middle East & Africa Influenza Vaccine Market Value (USD billion), by Country, 2025 & 2034
  • Figure 56: Middle East & Africa Influenza Vaccine Market Value Share (%), by Country, 2025
  • Figure 57: Global Influenza Vaccine Market Share (%), 2025